Clinical Report: Evaluating Cost Efficiency and Safety of Dose Rounding for Trastuzumab Deruxtecan
Overview
This study evaluates the cost savings and safety of dose rounding for trastuzumab deruxtecan in Chinese patients.
Background
Trastuzumab deruxtecan is a costly therapy for HER2-positive cancers, contributing to the financial burden on healthcare systems. Dose rounding strategies have been proposed to minimize drug waste and reduce costs, yet their safety and efficacy in real-world settings, particularly in China, remain underexplored.
Data Highlights
Group
Cost Savings (CNY)
Drug Waste (mg)
Adverse Events
Downward Rounding
897,840
0
Comparable
Upward Rounding
0
4,368.3
Comparable
No Rounding
0
0
Comparable
Key Findings
141 patients were analyzed with 829 administrations of trastuzumab deruxtecan.
Downward rounding resulted in cost savings of CNY 897,840.
Upward rounding avoided 4,368.3 mg of drug waste.
Dose deviations ranged from 0.10% to 9.97%, within the acceptable limit of 10%.
No statistically significant differences in adverse events were observed across the rounding strategies.
Clinical Implications
The study suggests that dose rounding of trastuzumab deruxtecan is a feasible strategy to reduce costs and drug waste in clinical practice. It highlights the importance of evaluating cost-saving measures while maintaining patient safety.
Conclusion
Dose rounding of trastuzumab deruxtecan can effectively reduce drug waste and pharmacy costs without compromising safety in Chinese patients. Further validation in larger studies is warranted.
